Federated Hermes
XGN icon

Federated Hermes’s Exagen XGN Stock Holding History

Federated Hermes’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,247
Closed -$13.7K – 2224
2025
Q3 		$13.7K Buy
+1,247
New +$11K ﹤0.01% 1850

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Federated Hermes's XGN Position: Q4 2025 in Review

Federated Hermes sold out of Exagen (XGN) in Q4 2025, closing a stake of 1,247 shares — an estimated $13.7K sold.

Federated Hermes first reported a position in XGN in Q3 2025 and held it in 1 quarter. The position peaked at $13.7K in Q3 2025. 80 funds tracked by Wall St. Rank hold XGN as of Q4 2025.

  • Federated Hermes reported no remaining Exagen position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 1,247 Exagen shares in Q4 2025, an estimated $13.7K.
  • Federated Hermes first reported a position in Exagen in Q3 2025 and held it in 1 quarter.
  • Federated Hermes's Exagen position peaked at $13.7K in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Exagen as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.